Cargando…

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer

Gefitinib showed response in phase II clinical trials and with better clinical response in lung cancer with activating mutations in the tyrosine kinase domain of the EGFR. Questions of toxicity and potential dosing regimens impede the use in a prevention setting. This study will provide scientific e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qi, Li, Ruichao, Chen, Xu, Lee, Sang Beom, Pan, Jing, Xiong, Donghai, Hu, Jiaqi, Miller, Mark Steven, Szabo, Eva, Lubet, Ronald A., Wang, Yian, You, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641144/ https://www.ncbi.nlm.nih.gov/pubmed/29069801 http://dx.doi.org/10.18632/oncotarget.19785

Ejemplares similares

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
por: Lubet, Ronald A., et al.
Publicado: (2018)

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
por: Lubet, Ronald A., et al.
Publicado: (2019)

Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents
por: Xiong, Donghai, et al.
Publicado: (2016)

Airway brushing as a new experimental methodology to detect airway gene expression signatures in mouse lung squamous cell carcinoma
por: Pan, Jing, et al.
Publicado: (2018)

Novel mutational landscapes and expression signatures of lung squamous cell carcinoma
por: Xiong, Donghai, et al.
Publicado: (2017)

Exosomal miRNAs as Novel Pharmacodynamic Biomarkers for Cancer Chemopreventive Agent Early Stage Treatments in Chemically Induced Mouse Model of Lung Squamous Cell Carcinoma
por: Zhou, Yu, et al.
Publicado: (2019)

Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention
por: Lee, Sang Beom, et al.
Publicado: (2023)

Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial
por: Balk, Jiska M, et al.
Publicado: (2015)

Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR‐Driven Lung Cancer
por: Huang, Mofei, et al.
Publicado: (2022)

Tumor intrinsic immunity related proteins may be novel tumor suppressors in some types of cancer
por: Xiong, Donghai, et al.
Publicado: (2019)

A gene expression signature of TREM2(hi) macrophages and γδ T cells predicts immunotherapy response
por: Xiong, Donghai, et al.
Publicado: (2020)

Reply to: “Inconsistent prediction capability of ImmuneCells.Sig across different RNA-seq datasets”
por: Xiong, Donghai, et al.
Publicado: (2021)

Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine
por: Pan, Jing, et al.
Publicado: (2017)

Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
por: Italiano, Antoine, et al.
Publicado: (2021)

A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2019)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children
por: Bunupuradah, Torsak, et al.
Publicado: (2015)

HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens
por: Kapadia, Shashi N, et al.
Publicado: (2018)

Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications
por: Kubitza, Dagmar, et al.
Publicado: (2016)

Analysis of the activity and safety of weekly low‐dose bevacizumab‐based regimens in heavily pretreated patients with metastatic breast cancer
por: Zhai, Xiaoyu, et al.
Publicado: (2018)

An open-label, randomized, 10 weeks prospective study on the efficacy of vitamin D (daily low dose and weekly high dose) in vitamin D deficient patients
por: Singh, Vikram, et al.
Publicado: (2019)

Minimum concentration of Amphotericin B in serum according to the formulation, dose, and daily or prolonged intermittent therapeutic regimen
por: Schiave, Leticia Aparecida, et al.
Publicado: (2020)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator
por: Pan, Jing, et al.
Publicado: (2019)

Among once-daily regimens, single tablet regimens (STRs) are associated with better adherence
por: Murri, R, et al.
Publicado: (2012)

1563. Population Pharmacokinetics and Pharmacodynamics of Daily and Extended Interval Dalbavancin Dosing Regimens for Salvage Therapy of Staphylococcus aureus Endocarditis: Mechanistic Modeling of Rabbit Infection Data to Support Human Dosing Regimens
por: Farkas, Andras, et al.
Publicado: (2019)

Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer
por: Xiong, Donghai, et al.
Publicado: (2018)

Chemoprevention of Lung Cancer with a Combination of Mitochondria-Targeted Compounds
por: Zhang, Qi, et al.
Publicado: (2022)

"Random" gentamicin concentrations do not predict trough levels in neonates receiving once daily fixed dose regimens
por: Boyle, Elaine M, et al.
Publicado: (2006)

Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
por: Macdougall, Iain C
Publicado: (2007)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
por: Qin, Yijia, et al.
Publicado: (2016)

Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment
por: Xue, Cong, et al.
Publicado: (2015)

Efficacy and Patient Satisfaction of Dipeptidyl Peptidase-4 Inhibitor After Switching From Once-Daily DPP-4 Inhibitor to Once-Weekly Regimen
por: Suzuki, Katsunori, et al.
Publicado: (2018)

Pulmonary Aerosol Delivery of Let‐7b microRNA Confers a Striking Inhibitory Effect on Lung Carcinogenesis through Targeting the Tumor Immune Microenvironment
por: Zhang, Qi, et al.
Publicado: (2021)

Rhabdomyolysis Caused by Gefitinib Overdose
por: Obayashi, Shohei, et al.
Publicado: (2021)

Gefitinib: Dermatitis: case report
Publicado: (2022)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sejalnrg3t7shgpb5smgk0nd38